| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Dimethyl lithospermate B targets sodium channels, acting as a selective agonist. It slows the inactivation of the sodium current (INa), leading to an increased inward current during the early phases of the action potential (AP). This effect on sodium channels is its primary mechanism of action, though its mode of action is considered unknown.
|
|---|---|
| ln Vitro |
In vitro, Dimethyl lithospermate B demonstrates potent activity as a sodium channel agonist. Its ability to slow sodium channel inactivation is a key finding, which could have implications for treating conditions where sodium channel function is impaired. It also shows potent antioxidant activity, which is a common feature of polyphenols from Salvia miltiorrhiza.
|
| ln Vivo |
In vivo, Dimethyl lithospermate B is believed to contribute to the pharmacological effects of Salvia miltiorrhiza, which is used for cardiovascular and metabolic disorders. Its sodium channel agonist activity suggests it could have positive inotropic effects, potentially improving heart function. Its antioxidant properties may contribute to its protective effects against oxidative stress.
|
| Enzyme Assay |
The in vitro electrophysiological assay for Dimethyl lithospermate B is the primary method for studying its mechanism. This involves the patch-clamp technique, where sodium currents are recorded from cells expressing sodium channels (e.g., HEK293 cells). The compound is applied, and its effect on the kinetics of sodium channel activation and inactivation is measured. The slowing of inactivation is quantified.
|
| Cell Assay |
In vitro cell culture studies for Dimethyl lithospermate B are limited. Its effects could be studied in cardiomyocytes or neuronal cells, where sodium channels are abundant. Cells are treated with the compound, and changes in action potential duration or firing rate are measured using electrophysiological techniques. Its antioxidant activity can be assessed by measuring its ability to scavenge free radicals in cell-free systems.
|
| Animal Protocol |
In vivo animal experiments for Dimethyl lithospermate B are not specifically established. However, as a component of Salvia miltiorrhiza, its effects may be inferred from studies on the herb. Animal models of myocardial ischemia or diabetes are used to study the cardioprotective and antidiabetic effects of the extract, which likely involve compounds like Dimethyl lithospermate B.
|
| ADME/Pharmacokinetics |
Dimethyl lithospermate B has a molecular weight of 746.67 g/mol and is a solid compound. It is practically insoluble in water (0.013 g/L at 25°C) and is soluble in organic solvents like DMSO. It is typically stored at 2-8°C for long-term stability and is stable for up to 24 months when stored as directed.
|
| Toxicity/Toxicokinetics |
Toxicological data for Dimethyl lithospermate B are limited. As a natural product and research compound, it is not intended for human use. Comprehensive toxicological studies have not been reported. Standard precautions for handling chemical research reagents should be followed.
|
| References |
|
| Additional Infomation |
It has been reported that dmLSB exists in plants of the genus Salvia przewalskii, and relevant data are available for reference.
Dimethyl lithospermate B is a research compound with no clinical approval. It is a valuable tool for studying sodium channel function and the pharmacology of polyphenols from Salvia miltiorrhiza. Its selective sodium channel agonist activity and antioxidant properties make it a compound of interest for research into cardiovascular and metabolic diseases, though further studies are needed to explore its therapeutic potential. |
| Molecular Formula |
C38H34O16
|
|---|---|
| Molecular Weight |
746.6670
|
| Exact Mass |
746.184
|
| CAS # |
875313-64-7
|
| PubChem CID |
11422787
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
968.3±65.0 °C at 760 mmHg
|
| Flash Point |
300.5±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.687
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
54
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC(=O)[C@@H](CC1=CC(=C(C=C1)O)O)OC(=O)/C=C/C2=C3[C@@H]([C@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)OC
|
| InChi Key |
DHYLGBJCEGEBGQ-QHIXFNMVSA-N
|
| InChi Code |
InChI=1S/C38H34O16/c1-50-36(47)29(15-18-3-8-22(39)26(43)13-18)52-31(46)12-7-20-5-11-25(42)35-32(20)33(34(54-35)21-6-10-24(41)28(45)17-21)38(49)53-30(37(48)51-2)16-19-4-9-23(40)27(44)14-19/h3-14,17,29-30,33-34,39-45H,15-16H2,1-2H3/b12-7+/t29-,30-,33+,34-/m1/s1
|
| Chemical Name |
[(2R)-3-(3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl] (2S,3S)-2-(3,4-dihydroxyphenyl)-4-[(E)-3-[(2R)-3-(3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]oxy-3-oxoprop-1-enyl]-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~133.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3393 mL | 6.6964 mL | 13.3928 mL | |
| 5 mM | 0.2679 mL | 1.3393 mL | 2.6786 mL | |
| 10 mM | 0.1339 mL | 0.6696 mL | 1.3393 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
